ARVINAS, INC.
Clinical-stage biopharma developing therapeutics based on targeted protein degradation.
ARVN | US
Overview
Corporate Details
- ISIN(s):
- US04335A1051
- LEI:
- Country:
- United States of America
- Address:
- 395 WINCHESTER AVE, 6511 NEW HAVEN
- Website:
- https://www.arvinas.com/
Description
Arvinas, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics based on targeted protein degradation. The company is a leader in this field, utilizing its proprietary PROTAC® (PROteolysis TArgeting Chimera) platform to create a new class of drugs. This technology is designed to harness the body's own cellular machinery to selectively remove disease-causing proteins. Arvinas is advancing a pipeline of investigational therapies targeting debilitating and life-threatening diseases, with a primary focus on oncology and neuroscience. The company was the first in its field to advance an investigational drug through a pivotal trial and submit a New Drug Application to U.S. regulators.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ARVINAS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ARVINAS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ARVINAS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
